These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10123669)

  • 41. Fast track to MS drug.
    Sheridan C
    Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635
    [No Abstract]   [Full Text] [Related]  

  • 42. Piercing the veil of corporate secrecy about clinical trials.
    Lemmens T
    Hastings Cent Rep; 2004; 34(5):14-8. PubMed ID: 15553393
    [No Abstract]   [Full Text] [Related]  

  • 43. Barriers to clinical trials vary according to the type of trial and the institution.
    Govindarajan R; Young JW; Harless CL; Hutchins LF
    J Clin Oncol; 2007 Apr; 25(12):1633-4; author reply 1634. PubMed ID: 17443010
    [No Abstract]   [Full Text] [Related]  

  • 44. Biologics target bad bugs.
    Extance A
    Nat Rev Drug Discov; 2010 Mar; 9(3):177-8. PubMed ID: 20190776
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharma consolidates its grip on post-antibody landscape.
    Sheridan C
    Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
    Couzin J
    Science; 2004 Dec; 306(5705):2170. PubMed ID: 15618492
    [No Abstract]   [Full Text] [Related]  

  • 47. Lymphoma treatment approved.
    AIDS Patient Care STDS; 1998 Mar; 12(3):231. PubMed ID: 11361944
    [No Abstract]   [Full Text] [Related]  

  • 48. Off-label uses of monoclonal antibodies for treatment of B-cell lymphoid or myeloid malignancies.
    Tecnologica MAP Suppl; 2001 Jul; ():14-7. PubMed ID: 11718149
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeted therapy trials: approval strategies, target validation, or helping patients?
    Hoff PM; Ellis LM
    J Clin Oncol; 2007 May; 25(13):1639-41. PubMed ID: 17470854
    [No Abstract]   [Full Text] [Related]  

  • 50. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Who should receive antiendotoxin monoclonal antibody therapy?
    Hardin TC; DiPiro JT
    Clin Pharm; 1992 Mar; 11(3):255-6. PubMed ID: 1611815
    [No Abstract]   [Full Text] [Related]  

  • 52. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ertapenem (Invanz)--a new parenteral carbapenem.
    Med Lett Drugs Ther; 2002 Mar; 44(1126):25-6. PubMed ID: 11941264
    [No Abstract]   [Full Text] [Related]  

  • 55. The invisible hand of the marketing department.
    CMAJ; 2002 Jul; 167(1):5, 7. PubMed ID: 12137082
    [No Abstract]   [Full Text] [Related]  

  • 56. Patients, physicians, and clinical trials: the other side of the coins.
    Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
    J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
    [No Abstract]   [Full Text] [Related]  

  • 57. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 58. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.
    Marks L
    MAbs; 2012; 4(3):403-12. PubMed ID: 22531443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 60. Charity's first move is drug investment.
    Mitchell P
    Nat Med; 2002 Apr; 8(4):314. PubMed ID: 11927921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.